Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,131 public trials 2,034 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL

NCT04881838

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Shanghai Children's Medical Center Shanghai, China

View Trial Details

Active, not recruiting

BNHL-2015 for Children or Adolescents in China

NCT02405676

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations: West China Second University Hospital of Sichuan University Chengdu, Sichuan, China

View Trial Details

Active, not recruiting

FT819 in Subjects With B-cell Malignancies

NCT04629729

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +20 more
Locations: University of Alabama at Birmingham Birmingham, Alabama, United States

Mayo Arizona Phoenix, Arizona, United States

UC Davis Davis, California, United States

Scripps Green Hospital La Jolla, California, United States

View all 18 locations

View Trial Details

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

NCT06357975

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, not recruiting

CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma

NCT04726501

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations: West China Second University Hospital, Sichuan University, Chengdu, China Chengdu, China

Nanjing Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China Nanjing, China

Shanghai Children's Medical Center Shanghai, China

View Trial Details

Active, not recruiting

Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma

NCT07480837

Conditions: B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China

View Trial Details

Active, not recruiting

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

NCT07480850

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing, Beijing, China

View Trial Details

Active, not recruiting

LBL-2016 for Children or Adolescents in China

NCT02845882

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: West China Second University Hospital Chengdu, China

Shanghai Children's Medical Center Shanghai, China

View Trial Details

Active, not recruiting

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

NCT03478462

Conditions: Astrocytoma, Brain Diseases, Brain Neoplasms, +62 more
Locations: Lucile Packard Children's Hospital Palo Alto, California, United States

Memorial Sloan Kettering Cancer Center New York, United States

Duke University Chapel Hill, North Carolina, United States

Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States

View Trial Details

Active, not recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of Arkansas Little Rock, Arkansas, United States

City of Hope Duarte, California, United States

UC San Diego Health Moores Cancer Center San Diego, California, United States

University of California San Francisco (UCSF) San Francisco, California, United States

View all 106 locations

View Trial Details

Lymphoproliferative Disorders

Lymphoproliferative Disorders trial results

Related conditions